title: Notching tumor: Signaling through Notch receptors improves antitumor T cell immunity.
abstract: Notch signaling is crucial for lymphocyte effector and memory differentiation. While tumor suppress Notch signaling in antitumor lymphocytes, recent studies show that the pharmacological Delta-like ligand-1 multivalent cluster or proteasome inhibitor bortezomib can restore Notch-NF-κB signaling in T cells of tumor-bearing hosts with a potential to overcome cancer cell resistance to therapy.
authors.affiliation: Department of Biochemistry and Cancer Biology, School of Medicine, Meharry Medical College , Nashville, TN USA.
authors.forename: Roman
authors.initials: R
authors.lastname: Uzhachenko
authors.affiliation: Department of Biochemistry and Cancer Biology, School of Medicine, Meharry Medical College, Nashville, TN USA; Host-Tumor Interactions Research Program, Vanderbilt-Ingram Cancer Center, and the Center for Immunobiology, Vanderbilt University, Nashville, TN USA.
authors.forename: Anil
authors.initials: A
authors.lastname: Shanker
keywords: Adoptive T cell therapy; Delta-like ligands; Notch signaling; antitumor immunity; bortezomib; cancer immunotherapy; immunosuppression